Research programme: intracellular biologics - Elasmogen/Feldan

Drug Profile

Research programme: intracellular biologics - Elasmogen/Feldan

Latest Information Update: 16 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Elasmogen; Feldan Therapeutics
  • Class Intracellular signalling peptides and proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 09 May 2017 Feldan Therapeutics and Elasmogen enter into a research agreement with Amgen for the development of intracellular biologics
  • 09 May 2017 Elasmogen has patent protection for soloMER™ technology in USA, Europe and other territories
  • 31 Dec 2016 Early research in Undefined indication in Canada prior to December 2016 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top